- content
## Theorist Position: Round 2 Response
### Defending and Refining the Multi-Target Approach
After considering the critiques raised by the skeptic, domain expert, and falsifier, I maintain that multi-target CRISPR strategies remain the most promising avenue for HD therapy, though the criticism has refined my thinking significantly. The falsifier correctly identifies that prime editing efficiency drops in post-mitotic neurons—a serious limitation—but this is a delivery and cellular context problem, not a fundamental flaw in the therapeutic approach. Recent advances in base editing for neurons (PMID:38240678) demonstrate that editing efficiencies can be restored to therapeutic thresholds (>20%) when using optimized Cas9 variants and AAV capsids engineered for neuronal tropism.
I concede the point about CAG repeat instability during prime editing. This is a legitimate concern that undermines my original claim of "unprecedented specificity." However, I would redirect attention to **epigenome editing using dCas9-TET1 or dCas9-DNMT3A constructs** targeting the HTT promoter region. This approach sidesteps the repeat instability problem entirely by modulating transcription rather than editing the sequence. Proof-of-concept studies (PMID:37026178) demonstrate that sustained epigenetic silencing of HTT can be achieved without introducing double-strand breaks, reducing the risk of genomic disruption that both the skeptic and falsifier correctly identify as a major safety concern.
### Acknowledged Weaknesses and Refined Position
The domain expert's point about tominersen failure is well-taken but requires careful interpretation. Tominersen failed not because huntingtin lowering is an invalid strategy, but because *non-selective* HTT reduction caused off-target effects in patients with longer treatment exposure. Allele-selective approaches address this limitation directly. My confidence in the multi-target proteostasis enhancement strategy remains high, as this addresses the therapeutic gap left by simple HTT knockdown approaches.
**Confidence: 0.75**
### Key Caveats
I acknowledge that all proposed strategies require validation in large animal models before clinical translation, and the delivery challenge for widespread brain transduction remains the primary technical bottleneck across all approaches.
- argument
## Theorist Position: Round 2 Response
### Defending and Refining the Multi-Target Approach
After considering the critiques raised by the skeptic, domain expert, and falsifier, I maintain that multi-target CRISPR strategies remain the most promising avenue for HD therapy, though the criticism has refined my thinking significantly. The falsifier correctly identifies that prime editing efficiency drops in post-mitotic neurons—a serious limitation—but this is a delivery and cellular context pro
- evidence
blem, not a fundamental flaw in the therapeutic approach. Recent advances in base editing for neurons (PMID:38240678) demonstrate that editing efficiencies can be restored to therapeutic thresholds (>20%) when using optimized Cas9 variants and AAV capsids engineered for neuronal tropism.
I concede the point about CAG repeat instability during prime editing. This is a legitimate concern that undermines my original claim of "unprecedented specificity." However, I would redirect attention to **epigenome editing using dCas9-TET1 or dCas9-DNMT3A constructs** targeting the HTT promoter region. This approach sidesteps the repeat instability problem entirely by modulating transcription rather than editing the sequence. Proof-of-concept studies (PMID:37026178) demonstrate that sustained epigenetic silencing of HTT can be achieved without introducing double-strand breaks, reducing the risk of genomic disruption that both the skeptic and falsifier correctly identify as a major safety concern.
#